IMAB stock price target lowered at H.C. Wainwright after ASCO readout (NASDAQ:IMAB)
seekingalpha.com
finance
2022-05-31 17:14:59

naphtalina/iStock via Getty Images Commenting on a recent data readout announced by Chinese biotech I-Mab (NASDAQ:IMAB) for its CD73 antibody uliledlimab, H.C. Wainwright issued mixed views on the lung cancer candidate on Tuesday. The initial data from the ongoing trial on Thursday is scheduled for a presentation at this week's 2022 American Society of Clinical Oncology (ASCO) Annual meeting sent I-Mab (IMAB) shares sharply lower last week. Reiterating the Buy rating on the stock, the analyst Andrew S.
